Summary
83 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 68 USD is left as net profit.
- Revenue grew by 18% a year over the last 3 years.
- You pay 0.0 USD for 1 USD of yearly profit, little for its sector.
- It bought back its own shares for $153.0M in the last fiscal year, 169,611% of its market value.
What to watch
- It earns only 3.9 USD a year on every 100 USD of invested capital.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 0.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.8% a year over 5 years. Over the last 3 years it grew by 18% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 9.3 USD
- Research and development 14 USD
- Sales and administration 42 USD
- Taxes and other -33 USD
- Net profit 68 USD
Net profit, industry median (Medical - Pharmaceuticals) 4.8 USD
Out of every 100 USD of revenue, 68 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 8.6 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 4
- Sell 1
No analyst has published a price target.
58% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Royalty 33%
- Intangible Royalty Assets 27%
- Contract Revenue 14%
- Material Sales, Captisol, Core 8.1%
- Royalty, Kyprolis 7.2%
- Other 12%
By region
The company reports no revenue by region.
Royalty brings in 33% of revenue.
Segments in detail